

# Jeremy D Gale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11352118/publications.pdf>

Version: 2024-02-01

12  
papers

573  
citations

1040056

9  
h-index

1281871

11  
g-index

13  
all docs

13  
docs citations

13  
times ranked

970  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. <i>Nature Metabolism</i> , 2020, 2, 1135-1148.	11.9	327
2	Alpha 2 Delta ( $\alpha 2\delta$ ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome. <i>Frontiers in Pharmacology</i> , 2011, 2, 28.	3.5	49
3	Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study. <i>Pharmaceutical Statistics</i> , 2015, 14, 205-215.	1.3	41
4	Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. <i>Kidney International Reports</i> , 2018, 3, 1316-1327.	0.8	38
5	Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 333-342.	1.2	23
6	A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. , 2018, 59, 2659.		18
7	Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study. <i>Clinical and Translational Science</i> , 2021, 14, 671-682.	3.1	18
8	Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. <i>Lancet Rheumatology</i> , The, 2021, 3, e204-e213.	3.9	15
9	Pregabalin inhibits accelerated defecation and decreased colonic nociceptive threshold in sensitized rats. <i>European Journal of Pharmacology</i> , 2010, 643, 107-112.	3.5	13
10	Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1498-1508.	1.9	10
11	Tachykinin NK1 receptor antagonists for the control of chemotherapy-induced nausea and vomiting. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1837-1847.	5.0	9
12	Histological sub-classification of cirrhosis using collagen proportionate area in patients with chronic hepatitis C. <i>Liver International</i> , 2021, 41, 1608-1613.	3.9	3